What is the best treatment option after progression to chemotherapy/immunotherapy (chemo/IO) as first-line treatment for PD-L1–positive lung adenocarcinoma with no sensitizing mutations?
Bruno Saldivar-Oviedo
Advertisement
Articles by Bruno Saldivar-Oviedo
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on CancerNetwork
1
58 An Evidence-Based Self-Management Planner for Patients With Metastatic Triple-Negative Breast Cancer: A Multi-Channel Dissemination Initiative
2
From Conference to Practice: Top 5 Takeaways From EHA 2026
3
57 Altered Biomechanics Drives Outcome in Breast Cancer: A New Avenue for Oncology Biomarkers
4
3 Things You Should Know About Using Selective Estrogen Receptor Degraders in Hormone Receptor–Positive, HER2-Negative Advanced Breast Cancer
5